Selumetinib added to saracatinib overcomes the EGFR/HER2/ERBB2–mediated bypass activation of MEK/MAPK that is observed with saracatinib alone and targets tumor-initiating ovarian cancer populations, supporting combined Src–MEK inhibition therapeutics for future trials [58]. Here, ERBB2 is linked to neoplasm.